Advanced Biomed Inc.
Advanced Biomed Inc. (ADVB): 7 pipeline candidates · ~62 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
62.3 months
D/E 0.16 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for Advanced Biomed Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.4M
Cash
$2.6M
Quarterly Burn
$240K
Runway
62.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| a+lcguard | Preclinical |
| gastric emptying breath test | — |
| hiresolution bionic ear system | Approved |
| model 721a ultraviolet light-absorbing lens | Approved |
| sauflon pw | Approved |
| simpson-robert family of coronary dilatation catheters | — |
| softherm sol | Approved |
Frequently asked questions
How many drug candidates are in Advanced Biomed Inc.'s pipeline?
Advanced Biomed Inc. (ADVB) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Advanced Biomed Inc.'s lead drug candidate?
Advanced Biomed Inc.'s most advanced tracked candidate is a+lcguard (Preclinical) for Early screening of lung cancer.
What is Advanced Biomed Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Advanced Biomed Inc. has approximately 62.3 months of cash runway.
What is Advanced Biomed Inc.'s market capitalization?
Advanced Biomed Inc.'s market capitalization is approximately $7.4M.
Who is the CEO of Advanced Biomed Inc.?
Dr. Yi Lu Ph.D. is the chief executive officer of Advanced Biomed Inc. (ADVB).
Get the full picture on Advanced Biomed Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.